Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Total revenue	$ 3,166	$ 1,928
Operating expenses:
Cost of goods sold	1,285	206
Research and development	4,832	4,833
Selling, general and administrative	10,040	9,994
Amortization of intangible assets	477	121
Change in fair value of contingent consideration	365	0
Total operating expenses	16,999	15,154
Operating loss	(13,833)	(13,226)
Other income (expense), net:
Interest income	30	3
Interest expense	(277)	(132)
Other income (expense)	17	(25)
Total other income (expense), net	(230)	(154)
Net loss before income taxes	(14,063)	(13,380)
Provision for income tax expense	56	0
Net loss	(14,119)	(13,380)
Comprehensive loss	$ (14,119)	$ (13,380)
Net loss per share, basic (in USD per share)	$ (0.54)	$ (0.71)
Net loss per share, diluted (in USD per share)	$ (0.54)	$ (0.71)
Weighted-average number of shares outstanding, basic (in shares)	26,115,986	18,829,534
Weighted-average common shares outstanding, diluted (in shares)	26,115,986	18,829,534
Net product revenues
Revenue from contract with customer	$ 2,411	$ 718
License and collaboration revenues
Revenue from contract with customer	585	1,174
Government research contracts and grants revenue
Government research contracts and grants revenue	$ 170	$ 36